ARTICLE | Clinical News
DN-101: Phase III started
April 17, 2006 7:00 AM UTC
Novacea started the double-blind, international Phase III ASCENT-2 trial in about 900 patients comparing DN-101 plus Taxotere vs. standard therapy of Taxotere plus prednisone. Taxotere is marketed by...